INTRODUCTION Adenosine and its receptors
Adenosine receptors or receptor-mediated effects have been demonstrated in virtually every tissue or organ examined [1, 2] . Adenosine, a purine nucleoside, is produced in response to metabolic stress and cell damage, and elevations in extracellular adenosine are found in conditions of ischemia, hypoxia, inflammation, and trauma (reviewed in ref. [3] ). The dominant pathway leading to high extracellular adenosine levels during metabolic stress is release of precursor adenine nucleotides (mostly ATP) from the cell, followed by extracellular catabolism to adenosine by a cascade of ectonucleotidases, including CD39 (nucleoside triphosphate diphosphorylase) and CD73 (5Ј-ectonucleotidase [4 -12] ). Another significant source of extracellular adenosine is intracellular adenosine, which is released through nucleoside transporters when intracellular adenosine levels rise. This occurs mostly as a result of degradation of intracellular ATP in ischemic conditions. Adenosine bioavailability is limited by its catabolism to inosine by adenosine deaminase or by salvage following cellular uptake via adenosine kinase.
Adenosine produces a wide range of physiological responses by binding to and activating four cell surface adenosine receptors, designated as A 1 , A 2A , A 2B , and A 3 . The adenosine receptors contain seven transmembrane domains and couple to intracellular GTP-binding proteins (G proteins). Adenosine, the endogenous agonist, can activate A 1 , A 2A , and A 3 receptors with EC 50 in the 0.2-to 0.7-M range, whereas the potency of adenosine at A 2B receptors is lower (EC 50 : 24 M) [13] . As physiological adenosine concentrations rarely exceed 1 M, physiological levels of adenosine can activate A 1 , A 2A , and A 3 receptors, whereas A 2B receptor activation requires pathophysiological conditions. In general, A 1 and A 3 receptors couple to pertussis toxin-inhibited G i/o proteins, the activation of which results in decreases in intracellular cAMP levels. A 2A and A 2B receptors couple to G s proteins and stimulate adenylyl cyclase and cAMP accumulation. A 2B receptors can also couple to G q , resulting in phospholipase C activation and stimulation of the inositoltrisphosphate and diacylglycerol pathways. Adenosine receptors couple to these various pathways in a manner that is highly cell type-dependent and temporally regulated [1, 2] . This receptor complexity reflects the multifaceted role that adenosine has in health and disease.
Regulation of A 2A receptor expression and function
A 2A receptors are found ubiquitously in the body, and their expression is highest in the immune system and the striatopallidal system in the brain [1, 2] . The A 2A receptor gene consists of multiple exons, which encode alternative transcripts, whose expression is driven by at least four independent promoters. The regulation of these promoters is now under intense investigation, and it is becoming increasingly clear that A 2A receptor gene expression is highly responsive to alterations in the extracellular environment. In this regard, A 2A receptor expression is exquisitely sensitive to changes in the concentrations of exogenous and endogenous factors involved in inflammation. Exposure of macrophages to LPS induced a dramatic increase in the expression of A 2A receptor mRNA and protein, effects that were brought about through activation of the transcription factor NF-B [14] . Two endogenous inducers of the NF-B system, TNF-␣ and IL-1␣, potently up-regulated A 2A receptor expression on monocytes as well, and this increase in receptor expression was reflected in an increased responsiveness to agonists in initiating downstream signaling events [15] . However, the fact that the increase in receptor functionality following exposure to TNF-␣ was disproportionately greater when compared with the increase in receptor expression suggested additional regulatory levels. In fact, subsequently, it was found that TNF-␣ can preempt A 2A receptor desensitization by preventing translocation of G protein-coupled receptor kinase 2 and ␤-arrestin to the plasma membrane, thereby further augmenting receptor function [16] . In addition to bacterial products and cytokines, a recent study demonstrated that A 2A receptor expression was induced by heme oxygenase-1-derived carbon monoxide in macrophages, augmenting the sensitivity of macrophages toward the anti-inflammatory effect of adenosine [17] .
Signaling pathways activated by A 2A receptors A 2A receptors, similar to other G s protein-coupled receptors, signal through activation of adenylyl cyclase, generation of intracellular cAMP, and activation of protein kinase A (PKA), which can then phosphorylate and thereby activate the transcription factor CREB [18] , directly affecting gene expression by binding to gene promoters or indirectly, by competing with NF-B for an important cofactor, CREB-binding protein [19] . In addition, we have recently demonstrated that another transcription factor, CCAAT enhancer-binding protein ␤, is responsible for the stimulatory effect of A 2A receptor agonists on IL-10 production [20] .
Alternative to the canonical cAMP-PKA pathway, A 2A receptors can also mediate activation of MAPKs and PKC [19] . Importantly, this PKC pathway was recently implicated as a crucial mechanism that is required for the induction of hypoxia-inducible factor 1 in macrophages [21] .
Pharmacology of A 2A receptors
Transfection of Chinese hamster ovary, COS-7, or human embryonic kidney 293 cells with recombinant adenosine receptors had been widely used as a useful model in defining the selectivity of various adenosine receptor ligands [22] [23] [24] . Based on this approach, CGS21680 {2-[p-(2-carboxyethyl)phenylethylamino]-5Ј-N-ethyl-carboxamidoadenosine} was identified first as a relatively selective agonist of A 2A receptors [22] . However, as these cell types express low levels of G proteins endogenously when compared with primary cells, studies subsequently used cotransfection of G proteins to refine the pharmacology of A 2A receptors [25] . Studies using this technique by Linden and coworkers [25] have revealed that ATL146e (4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydrofuran-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylicacid methyl ester) is a markedly more selective agonist of A 2A receptors than CGS21680, and it has an ϳ400-fold and ϳ220-fold selectivity for A 2A over A 1 receptors and A 3 receptors, respectively. Selective antagonists for the A 2A receptor are also available, and they include ZM241385 (4-{2- [ 
Adenosine governs immunity through A 2A receptor activation on immune cells
Recent studies indicate that adenosine is emerging as a key regulatory molecule, mostly protective but in certain scenarios injurious, in the pathophysiology of inflammatory diseases. In fact, adenosine receptors are expressed densely on virtually all cell types that are involved in orchestrating an inflammatory/ immune response, and these cell types include monocytes/ macrophages [15, 27] , dendritic cells [28, 29] , mast cells [30 -33] , neutrophils [34 -36] , platelets [37] , endothelial cells [38, 39] , eosinophils [40, 41] , epithelial cells [42, 43] , and fibroblasts [44] , as well as lymphocytes [45] [46] [47] , NK cells [48 -50] , and NKT cells [51] . Through the multiple adenosine receptors on the various immune cells, adenosine can protect or damage tissues and organs depending on which receptor is stimulated. In addition to the regulation of the inflammatory/ immune response, recent studies have emphasized the role of adenosine in tissue restitution and wound healing. Roles for adenosine receptors in regulating inflammation had for long been deduced from studies with adenosine receptor ligands. Using adenosine receptor ligands alone, however, is a method fraught with the possibility of erroneous conclusions, owing to the fact that no ligand is fully selective for a particular adenosine receptor. The recent availability of mouse models engineered to harbor a deletion or overexpression of a specific adenosine receptor has proven critical in elucidating the function of different adenosine receptors. On the basis of these genetic studies, it is becoming increasingly recognized that A 2A receptors represent the major immunoregulatory arm of the adenosine-adenosine receptor system, and there is also general agreement that A 2A receptors serve to down-regulate inflammation and immunity. Numerous excellent reviews have summarized the role that A 2A receptors play in regulating the functions of the various cell types that participate in inflammation and immunity [5, [52] [53] [54] [55] . In the current review, we will attempt to focus on a different aspect of A 2A receptor function in inflammation and immunity, namely on how A 2A receptors govern the function of organs that are undergoing an inflammatory challenge caused by infection, ischemia, or trauma.
HEART
A 2A receptors are abundantly expressed in the heart, and cardiac myocytes [56, 57] , fibroblasts [58] , and endothelial cells [59] as well as infiltrating hematopoietic cells [60, 61] are the major cell types on which A 2A receptor expression has been detected. Reperfusion following an acute ischemic episode induces profound oxidative/nitrosative stress associated with a vigorous inflammatory response and dramatic increase in neutrophil adherence to reperfused endothelium, which leads to capillary plugging, edema, and reduction in coronary vascular flow [62] (Fig. 1) , and eventually, transmigration of neutrophils and T lymphocytes, effectors of ischemic injury, into the parenchyma. Multiple lines of evidence have indicated that A 2A receptors are critical for adenosine-mediated protection against ischemia-reperfusion injury in the heart [63] (Fig. 1) , most compelling of which is the observation that treatment with the selective A 2A receptor agonist ATL146e immediately after reperfusion of the coronary artery reduces infarct size in A 2A receptor wild-type (WT) but not knockout (KO) mice [60] . There is emerging evidence that A 2A receptor-mediated protection is achieved by prevention of the injurious, proinflammatory/immune response, and CD4
ϩ T lymphocytes appear to be the major targets of this protective effect. This notion of A 2A receptors on T cells transmitting protective signals is based on several observations. The first evidence implicating bone marrow-derived cells and thus T cells came following the observation that the infarct-sparing effect of ATL146e disappeared in chimeric A 2A receptor WT mice in which bone marrow had been replaced using bone marrow from A 2A receptor KO mice [60] . In addition, administration of ATL146e provided no reduction in infarct size in Rag-1-KO mice that lack T cells, and adoptive transfer of CD4 ϩ T cells from A 2A receptor WT but not KO mice into Rag-1-KO mice re-established the protective effect of ATL146e [61] . These studies also revealed that A 2A receptor stimulation attenuates the trafficking of neutrophils into the infarcted area, an effect that is secondary to decreased IFN-␥ production by infiltrating T cells (Fig. 1) .
LUNG
A 2A receptors are widely expressed in the lung [64] , where they exert a plethora of physiological regulatory effects, most of which are anti-inflammatory and reparative in nature. Attenuation of the inflammatory response and facilitation of subsequent wound healing by A 2A receptors in the lung can be targeted to numerous sites, which include resident macrophages [65] , bronchial epithelial cells [66 -68] , mast cells [69] , eosinophils [67] , neutrophils [67, 68] , and lymphocytes [67, 68] . Consistent with the ability of A 2A receptor activation to inhibit the proinflammatory function of most of these cell types [3, 52, 70 -74] , Fozard and coworkers [75] reported for the first time that A 2A receptor activation using a relatively selective agonist, CGS21680, moderated allergic airway inflammation induced by sensitization to OVA in a rat model of asthma. The salutary effect of A 2A receptor activation was also confirmed in OVA-sensitized mice, where exogenously administered CGS21680 prevented inflammatory cell influx into the airways [67] . Using A 2A receptor-deficient mice, Jamal Mustafa and associates [68] identified the adenosine A 2A receptor-cAMP axis as a potent, endogenous, anti-inflammatory signaling mechanism that mitigates airway reactivity and inflammatory cell infiltration following sensitization with ragweed. These studies offered mechanistic insight into the action of A 2A receptors by demonstrating that A 2A receptor deficiency produces increased activation of the proinflammatory transcription factor NF-B and augmented expression of inducible NO synthase.
In addition to exhibiting potent, ant-inflammatory functions in animal models of asthma and other chronic obstructive pulmonary diseases (COPDs), A 2A receptor activation has recently been appreciated for its ability in protecting the lung against acute lung failure and acute respiratory distress syndrome. In this regard, A 2A receptor activation using CGS21680 was shown to ameliorate lung injury and neutrophil sequestration caused by an episode of trauma in combination with hemorrhagic shock [76] . The lung-protective effect of endogenous adenosine acting through A 2A receptors was also reproduced in a model of LPS-induced acute respiratory distress syndrome [77] . Specifically, intratracheal injection of LPS into A 2A receptor KO mice led to a markedly increased inflammatory response when compared with WT mice, as indicated by 
GUT
The density of A 2A receptors in the intact gut is substantially lower than that in the lung [1] , partly as intestinal epithelial cells express mostly A 2B receptors [78] . Nevertheless, during a chronic inflammatory response, such as that which occurs during inflammatory bowel disease (IBD), a substantial number of immune cells are recruited to the inflamed tissue. In this regard, activation of A 2A receptors was recently found to prevent trafficking of immune cells into the intestinal mucosa of rabbits, in which colitis was induced by formalin-immune complex or SAMP1/YitFc mice, which develop IBD spontaneously [79] . The decrease in leukocyte infiltration following A 2A receptor stimulation in both models ameliorated the course of disease, as indicated by preserved mucosal architecture and villi. A 2A receptor activation also attenuated colitis in SCID mice that were transferred adoptively with disease-inducing CD45RB high CD4 ϩ T cells [80] . high CD4 ϩ T cells was inefficient in blocking the development of disease [80] . These results illustrate that A 2A receptors are required for regulatory cell function in colitis; however, the exact mechanisms remain poorly defined.
LIVER
In liver, studies have demonstrated A 2A receptors on Kupffer cells [81] , hepatocytes [82] , and hepatic stellate cells [83] . The pioneering study of Ohta and Sitkovsky [84] , describing the hepatoprotective effects of A 2A receptors by using A 2A receptor KO mice, ushered in an era of intense investigation of A 2A receptors in regulating not only liver function but also inflammation in general. The major discovery of this work was that endogenous adenosine by engaging A 2A receptors has a nonredundant role in the attenuation of inflammatory liver damage induced by Con A. Mice deficient in A 2A receptors displayed elevated and prolonged production of proinflammatory cytokines, including TNF-␣ and IFN-␥, which was associated with increased biochemical and histological signs of liver injury. Liver-protecting properties of A 2A receptors were also confirmed in carbon tetrachloride-induced, acute hepatotoxicity [84] .
Ischemia-reperfusion injury of the liver is a clinically important manifestation of various surgical interventions, including liver transplantation, trauma repair, or partial hepatic resection. Inflammatory events that take place during reperfusion lead to disruption of the vascular endothelium, platelet aggregation, activation of immune cells, and cytokine and chemokine secretion. Pharmacological activation of A 2A receptors with ATL146e during this reperfusion phase strongly depressed liver inflammation, as demonstrated by reduced neutrophil infiltration, as well as decreased up-regulation of cytokine and chemokine gene expression [85] . These antiinflammatory effects could be correlated with improved liver function, as indicated by decreased serum alanine aminotransferase levels in drug-treated mice. The protective effect of ATL146e was abolished by genetic and pharmacological inactivation of A 2A receptors, confirming involvement of A 2A receptors [85] . In addition, A 2A receptor KO mice display heightened indices of injury, indicating that endogenous adenosine also imparts protection from injury. Subsequent studies using a bone marrow chimeric approach revealed that protection could be attributed to A 2A receptors on bone marrow-derived cells [86] . The reason for this proposition was that no protection was noted when A 2A agonists were administered to chimera mice that do not express A 2A receptors on bone marrow cells, and substantial protection was observed in chimeras that expressed A 2A receptors only on bone marrow cells. In addition, as depletion of NKT cells as well as blockade of the major NKT cell-activating molecule CD1d prevented the protective effect of ATL146e against liver reperfusion injury, a CD1d-mediated, NKT cell-dependent protection was considered as a cardinal mechanism in preventing liver injury by A 2A receptor stimulation [51] . This notion of a central role for NKT cells was further supported by studies showing that ATL146e afforded no reduction in liver injury in Rag-1-KO mice, but adoptive transfer of NKT cells from A 2A WT but not A 2A KO mice into Rag-1 KO recipients reinstated the protective action of ATL146e.
KIDNEY
A 2A receptors in kidney have been detected in the renal microvasculature [87] , as well as on mesangial [88] and tubular epithelial cells [89] . A 2A receptor activation by exogenous agonists or endogenous adenosine produced a dramatic reduction in renal injury following ischemia-reperfusion in rats [90, 91] and mice [92, 93] , as evidenced by improved morphology and renal function in agonist-treated animals. The protective effect of A 2A agonists was correlated with decreased endothelial cell adhesion molecule expression and neutrophil sequestration in the kidney parenchyma [91] . As the renal microvasculature responds to A 2A receptor stimulation by vasodilation, this increased blood flow in the renal microcirculation may potentially also contribute to renal protection by A 2A agonists. To discriminate between potential protective effects mediated by bone marrow-derived, inflammatory cells and vascular and other cells, Okusa and coworkers [93] generated A 2A receptor bone marrow chimera mice. Studies using these mice identified bone marrow-derived cells as primary cellular targets through which A 2A receptor activation affords protection from renal ischemia-reperfusion injury [93] . Although the particular cell type in the bone marrow has yet to be determined, A 2A receptor agonist-mediated protection is independent of activation of macrophage A 2A receptors, as the absence of an A 2A agonistmediated, protective effect in A 2A KO mice was not restored by reconstitution with WT macrophages [94] , which, however, do appear to play a role in the attenuating effect of A 2A receptor activation on the course of diabetic nephropathy [95] . The reason for this proposition is that tissue infiltration of macrophages, which are key players in driving kidney fibrosis, leading to renal dysfunction in diabetes, is strongly decreased by A 2A receptor agonist treatment in streptozotocin-induced diabetes in mice [95] . Additionally, A 2A receptor agonists reduce levels of the macrophage-derived cytokines MCP-1 and TNF-␣, both of which are important in affecting tissue fibrosis and glomelurosclerosis in diabetic mice [95] . Finally, it is interesting to note that diabetic nephropathy is more severe in A 2A receptor KO mice than WT mice, which suggests that endogenous adenosine might contribute to kidney protection from diabetes in a similar manner as it does in kidney ischemia-reperfusion injury [95] .
JOINTS
Low-dose methotrexate has been demonstrated to be an effective therapy for rheumatoid arthritis and is the most commonly used disease-modifying, antirheumatic drug in the treatment of this disease [96] . Several lines of evidence now indicate that the immunosuppressive and anti-inflammatory effects of methotrexate are a result of its capacity to increase extracellular adenosine levels [97, 98] . Moreover, recent results support the view that adenosine acting at A 2A receptors mediates some of the antiarthritic effects of methotrexate, as methotrexate was less effective in suppressing leukocyte accumulation in A 2A receptor KO than WT mice [99] . Potential cellular targets of A 2A receptor-mediated, anti-inflammatory effects in joints involve infiltrating leukocytes [99] , as well as chondrocytes [100] and synovial cells [101] .
CNS
A 2A receptors are expressed at high levels on neurons, inflammatory cells, and glial cells [102] . A 2A receptors on bone marrow-derived cells were recently incriminated as cardinal contributors to ischemic brain injury. Selective inactivation of A 2A receptors on bone marrow cells in chimeric mice protects against ischemic brain injury following middle cerebral arterial occlusion [103] . This protection is accompanied by a reduced expression of levels of macrophage-derived, proinflammatory mediators, such as IL-1, IL-6, and IL-12 in the brain, demonstrating a proinflammatory effect of A 2A receptor stimulation in this model. This injurious effect of A 2A receptor activation on bone marrow cells in the ischemic brain is unique, as A 2A receptor activation on bone marrow-derived cells is protective in the spinal cord [104] .
MULTIORGAN DYSFUNCTION AND SEPSIS
Similar to data with ischemia-reperfusion in peripheral organs, pharmacologic studies using exogenous A 2A receptor agonists in A 2A KO and WT mice show that the activation of A 2A receptors decreases organ injury and mortality, which is secondary to the overwhelming inflammation triggered by endotoxin [105, 106] . The recent demonstration of the tissue protection by endogenous adenosine acting at A 2A receptors in this hyperinflammatory model of sepsis [84, 107] further suggests the relevance of A 2A receptors to protection from hyperacute, systemic inflammation. The mechanistic link between A 2A receptor stimulation and protection from inflammatory organ injury is suggested by studies showing that A 2A receptor KO mice injected with LPS have increased plasma levels of proinflammatory TNF-␣ and activation of NF-B compared with similarly treated WT controls [84, 107] .
In contrast, in the clinically relevant cecal ligation and puncture (CLP) model of sepsis, which is characterized by an immune-suppressed state and insufficient bacterial clearance, A 2A receptor activation proved to be harmful, as stimulation of these receptors by endogenous adenosine decreased immune responsiveness, bacterial clearance, and survival [108, 109] . The decreased survival of mice caused by A 2A receptor stimulation was tightly associated with a capacity of A 2A receptor stimulation to increase bacterial burden, to augment immune cell apoptosis, and to increase production of the immunosuppressive cytokine IL-10. Recent in vitro studies have verified the essential role of A 2A receptor stimulation in eliciting IL-10 release in conjunction with bacterial infection, as A 2A receptor KO macrophages were unable to produce IL-10 following challenge with Escherichia coli, whereas the ability of WT cells to release IL-10 was intact [20] .
Taken together, our data that A 2A receptor activation increases mortality during CLP-induced sepsis [108] might seem contradictory to observations that A 2A receptor stimulation is beneficial in acute inflammation as a result of endotoxicosis. However, we believe the data seen as a whole suggest that differences in outcome in the two models are a result of immunosuppression being beneficial in acute inflammation/ ischemia but detrimental in more clinically relevant models of infection-induced sepsis, where mortality depends more on the loss of control of bacterial growth.
FUTURE OF A 2A RECEPTOR LIGANDS IN TREATING HUMAN DISEASE
A 2A receptor activation is now considered as one of the most potent, endogenous, anti-inflammatory signals in the body. The adenosine-A 2A anti-inflammatory axis is used as an endogenous means to control ischemia and inflammation-induced tissue injury, and attempts are being made to translate this anti-inflammatory mechanism to the clinical scenario. A 2A receptor agonists thus have high potential in treating ischemia and immune/inflammation-induced tissue injury in a wide variety of diseases, ranging from acute myocardial infarction to Crohn's disease ( Table 1) . In fact, an A 2A receptor agonist, MRE-0094, is in clinical trials for chronic, neuropathic, and diabetic foot ulcers, owing to the anti-inflammatory and wound-healing effects of A 2A receptor stimulation [110] . Clinical trials with ATL146e as an anti-inflammatory compound have also been initiated [111] .
There are several potential toxic effects that should be considered when testing A 2A receptor agonists as a therapeutic option to treat inflammatory and ischemic disease. For example, A 2A receptor agonists have been shown to adversely influence blood pressure, which is especially true for the widely used agonist CGS21680 [76] . Given the relatively moderate selectivity of CGS21680 toward A 2A when compared with A 1 receptors [22] , it is possible that A 1 receptors contribute to the adverse cardiovascular effect of this agent by directly impairing heart function [1, 2] . In addition, CGS21680 can cause vasodilation in some vascular beds in a NO-and K ATP channeldependent manner, and this vasodilation may also contribute to alterations in blood pressure [112] . Recently developed and more selective A 2A agonists, such as ATL146e, however, have the advantage of not decreasing blood pressure in rodents and larger mammals at doses that are fully effective inhibitors of inflammation [5] . A further potential issue with A 2A agonists stems from the fact that certain G protein-coupled receptors are down-regulated following prolonged administration of the agonist, preventing long-term efficacy [1, 2] . Such effects, however, have not been observed so far with in vivo administration of A 2A agonists, as exemplified by the effectiveness of A 2A agonists in chronic models of inflammation (Table 1) . [108] Alternatively, when there is need to provoke immune/inflammatory responses to rid the body of infections, as for example, in the immune-suppressed phase of sepsis, A 2A antagonists might be useful in enhancing the immune system's ability to fight and defeat invading pathogens (Table 1 ). In addition, the A 2A antagonists might be useful in treating ischemic events in the brain, based on the observation that activation of A 2A receptors on immune cells is responsible for mediating the deleterious effects of A 2A agonism in stroke [103] . Potential side-effects with the A 2A receptor antagonists might include increased blood pressure and inflammation; however, based on the results of recent trials with A 2A antagonists to treat patients with Parkinson's disease, A 2A antagonists seem to be well-tolerated and devoid of side-effects [113, 114] .
Taken together, despite some challenges that remain, optimism is currently high that A 2A receptor ligands will have a place in the treatment of many inflammatory diseases. 
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